

Full English text available at  
[www.actasdermo.org](http://www.actasdermo.org)

REVIEW

# [Translated article] Botulinum Toxin for Esthetic Use in Facial and Cervical Regions: A Review of the Techniques Currently Used in Dermatology

E. Vargas-Laguna\*, N. Silvestre-Torner, K. Magaletskyy-Kharachko

*Dermaniac, Clínica de Dermatología y Estética, Madrid, Spain*

Received 23 May 2024; accepted 14 July 2024

**KEYWORDS**  
Neuromodulators;  
Botulinum toxin;  
Rejuvenation

**Abstract** Botulinum toxin infiltration is one of the most widely performed esthetic procedures at the esthetic dermatology office. Although infiltrative techniques have been known for quite a few years, several changes have been described so far, mainly based on anatomical knowledge.

There are consensus guidelines available for injecting neuromodulators where one can see both the doses of toxin indicated for each muscle and the injection techniques. After a systematic review of the articles currently available, this article intends to summarize the infiltration techniques described both for the face and neck, while considering new anatomical considerations, new injection techniques published to date, and pearls and tricks for a better understanding of how to inject the botulinum toxin and improve our injection techniques. In our opinion it is important to treat the lower third to complement the treatment of the upper third and, in some patients, the partial blocking of some muscles of the middle third. With this comprehensive treatment of face and neck muscles we can achieve more natural and harmonious results.

© 2024 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**PALABRAS CLAVE**  
Neuromoduladores;  
Toxina botulínica;  
Rejuvenecimiento

**Toxina botulínica con fines estéticos en zonas facial y cervical: una revisión de las técnicas empleadas en dermatología**

**Resumen** La infiltración de toxina botulínica es uno de los procedimientos estéticos más realizados en la consulta de dermatología estética. Las técnicas infiltrativas se conocen desde años, aunque diversas modificaciones se han descrito hasta ahora, basadas sobre todo en los conocimientos anatómicos.

Existen guías de consenso de inyección de los neuromoduladores donde se pueden consultar tanto las dosis de toxina indicadas en cada músculo como las técnicas de inyección. Con este artículo pretendemos, tras hacer una revisión sistemática de artículos, resumir las técnicas

DOI of original article: <https://doi.org/10.1016/j.ad.2024.07.019>

\* Corresponding author.


E-mail address: [evargaslaguna@gmail.com](mailto:evargaslaguna@gmail.com) (E. Vargas-Laguna).

<https://doi.org/10.1016/j.ad.2024.12.007>

0001-7310/© 2024 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: E. Vargas-Laguna, N. Silvestre-Torner and K. Magaletskyy-Kharachko, [Translated article] Botulinum Toxin for Esthetic Use in Facial and Cervical Regions: A Review of the Techniques Currently Used in Dermatology, ACTAS Dermo-Sifiliográficas, <https://doi.org/10.1016/j.ad.2024.12.007>

33  
34  
35  
36  
37  
38  
39  
40  
41



de infiltración descritas tanto en la cara, como en el cuello, teniendo en cuenta las nuevas consideraciones anatómicas, las nuevas técnicas de inyección publicadas, así como perlas y trucos que nos permitan comprender mejor la inyección de la toxina botulínica, y mejorar nuestras técnicas de inyección. Consideramos importante el tratamiento del tercio inferior como complemento al tratamiento del tercio superior, y en algunos pacientes el bloqueo parcial de algunos músculos del tercio medio, de manera que el tratamiento integral de los músculos de la cara y del cuello nos permita conseguir resultados más naturales y armónicos.

© 2024 AEDV. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 42 Introduction

43 Botulinum toxin injection for facial rejuvenation is an  
44 increasingly demanded technique. There are different  
45 toxins authorized for esthetic use in Spain: Vistabel®  
46 (onabotulinumtoxin A), Bocouture® (incobotulinumtoxin  
47 A), Azzalure® (abobotulinumtoxin A), Alluzience® (abobo-  
48 tulinumtoxin A), and Letybo® (letybotulinumtoxin A). They  
49 all share the same mechanism of action, based on blocking  
50 the release of acetylcholine at the neuromuscular junction.  
51 Their differences are due to the accompanying molecules  
52 that stabilize the drug, modifying its presentation form  
53 (lyophilized or liquid), storage temperature, or immuno-  
54 genicity.

55 The indication of botulinum toxin in the product techni-  
56 cal data sheet is variable. Vistabel® and Bocouture® are the  
57 only ones with an indication for the frontal, glabellar, and  
58 orbicular regions. No toxin is approved for use in the middle  
59 third, lower third, or cervical region.

60 The goal of this article is to review the different infil-  
61 tration techniques described so far for the treatment of  
62 both the facial and cervical regions with botulinum toxin,  
63 considering anatomical factors. A systematic approach is  
64 proposed for the treatment of the different muscles of the  
65 face and neck, describing the infiltration points, depth,  
66 and recommended doses. The units referred to are those  
67 of onabotulinumtoxin A. Additionally, recommendations and  
68 precautions are included, depending on the characteristics  
69 of each patient.

## 70 Frontal muscle

### 71 Anatomy

72 It is the only facial elevator muscle. A bimodal movement  
73 has been described based on an imaginary line, known as  
74 the convergence line or Line C, which divides it into 2  
75 parts: an upper part responsible for lowering the eyebrows,  
76 and a lower part responsible for their elevation. This line  
77 is located 3 cm above the orbital rim in men and 4 cm in  
78 women. It typically coincides with the second horizontal  
79 wrinkle from the scalp implantation line.<sup>1</sup>

80 Contraction of the frontal muscle is responsible for hori-  
81 zontal wrinkles on the forehead.




Figure 1 Zigzag infiltration points of the frontal muscle (red), treatment points for lateral frontal wrinkles (green), and frontal elevation points (yellow).

### Position

82 Zigzag infiltrations are considered ideal, with the points  
83 marked according to the individual contraction pattern.  
84 They are distributed along the temporal fusion lines,<sup>2</sup> with  
85 a lower margin positioned 1.5 cm above the eyebrow at the  
86 mediopupillary line and 1.5–2 cm at the lateral zone of the  
87 muscle. This lower margin prevents diffusion to the eyelid  
88 elevator muscle (Fig. 1).

89 Infiltrations above the convergence line block the down-  
90 ward movement of the frontal muscle; the lower ones block  
91 the elevation of the eyebrows.<sup>3</sup>  
92

## Dose and depth of infiltration

The recommended doses range from 8 to 20 IU (international units) of onabotulinumtoxin A. Deep infiltrations, below the subfrontal fascia, are more effective.<sup>4</sup> The action halo of 2 IU of botulinum toxin is 1.5 cm.<sup>5</sup>

Above the convergence line, infiltrations should be deep, with a total of 2-4 IU per point. Below Line C, infiltrations should be subdermal with 0.5-2 IU per injection to maintain some eyebrow elevation function.


## Recommendations and precautions

1. Some functionality of the frontal muscle should be preserved to avoid a "frozen" look.
2. In men, due to greater muscle mass, higher doses are recommended.<sup>6</sup>
3. In patients with dermatochalasis or ptosis of the eyebrows, lower doses should be considered.
4. Mephisto's sign or look. This occurs when, after infiltrating the frontal muscle, there is excessive activity of its lateral portion. Three patterns of contraction of the frontal muscle's lateral portion are described to avoid its appearance:
  - o Type 1: No wrinkles in contraction or rest. No correction with infiltration of toxin in the lateral portion of the frontal muscle is needed.
  - o Type 2: Wrinkles present in contraction in the upper part of the lateral frontal muscle. Requires 1-2 IU infiltration in the area where the most wrinkles are seen.
  - o Type 3: Wrinkles present in contraction across the entire lateral portion of the frontal muscle. Infiltration of 1 IU is recommended in the upper part of the lateral frontal, and 1 IU in the lower part, always 0.5-1 cm above the lowest wrinkle. These should be avoided in older patients who use the frontal muscle for eyebrow and eyelid elevation.<sup>7</sup>
5. Arched concentric wrinkles that resemble the Wi-Fi icon (Wi-Fi lines): These correspond to very marked supra-ciliary wrinkles, either naturally or after blocking the medial part of the frontal muscle. Treatment includes infiltration below the described lower margin, with 1-2 very superficial points of 0.5-1 IU.
6. Elevation points. These aim to paralyze the cranial portion of the frontal muscle and consequently elevate the forehead. They correspond to 2 points on each side of the forehead, both 1.5 cm above the hairline: the first at the mediopupillary vertical line; the second, at the vertical line from the inner eye corner. A total of 8 IU per point is recommended.<sup>8</sup>

## Glabellar complex

### Anatomy

It is formed by 3 muscles: the corrugator, procerus, and depressor superciliar. The hyperfunction of the corrugator is responsible for vertical medial wrinkles. Horizontal wrinkles at the nasal root are due to the contraction of the procerus muscle, while diagonal medial wrinkles around the



**Figure 2** Treatment points for the glabella with the one21 (One21) technique (red and green), 3 points of an alternative technique with only 3 points (large red), infiltration points of the depressor superciliary muscle (blue).

eyebrow and inner canthus are due to the contraction of the depressor supercillii muscle.<sup>9</sup>

### Position

Almeida proposes treatment using 5-7 points depending on the contraction pattern. He describes the following patterns: "U" (the most common in women), "V" (the most common in men), converging arrows, Omega, and inverted Omega.<sup>10</sup> The incidence rate of eyelid ptosis in Almeida's technique is 3.1% (Fig. 2).

The "One21" technique, considered a variation of Almeida's, proposes treatment with between 3 and 12 points. It includes infiltration of the frontal muscle in its lower medial portion.

Cotofana suggests treatment of the glabellar complex with only 3 deep infiltration points at the insertion of the procerus and corrugator muscles. By treating only the medial part of the muscles, the risk of diffusion to the frontal muscle and ptosis of the eyebrows and/or eyelids is reduced.

### Dose and infiltration depth

The recommended doses for the glabellar complex range between 13 IU and 26 IU.

The procerus muscle should be injected deeply, almost in contact with the bone, with 4 IU up to 6 IU. The injection site is located in the middle of the line that connects to the can-

171 thal ligaments. In patients with long corrugators, a second  
172 site may be required, 1 cm above, with a more superficial  
173 injection of 2 IU.

174 The infiltration of the corrugator muscle varies according  
175 to the technique:

- 176 • Following the "One21" technique, a first infiltration  
177 should be performed at the medial origin of the muscle.  
178 This site is located on the vertical line from the inner can-  
179 thus, 1 cm above the orbital rim. The infiltration should  
180 be deep with doses of 4 IU up to 6 IU. The second point  
181 addresses the treatment of the lateral part of the mus-  
182 cle and is located at the midpoint between the vertical  
183 lines of the inner canthus and the mediopupillary line,  
184 1 cm above the orbital rim. This point should be infil-  
185 trated more superficially, with a dose of 2 IU up to 5 IU.  
186 For patients requiring infiltration of the medial and lower  
187 portion of the frontal muscle, another injection point is  
188 performed at the inner canthus, 2 cm above the eyebrows,  
189 coinciding with the lowest wrinkle on the forehead. Infil-  
190 tration should be at the superficial-medium level with 1 IU  
191 up to 2 IU.<sup>11</sup>
- 192 • Following Cotofana's technique, a single infiltration  
193 should be performed from the medial insertion of the mus-  
194 cle. It should be deep, in contact with the bone, with a  
195 total of 4 IU up to 6 IU. Some patients with long corru-  
196 gators may need 2 additional points at the upper edge  
197 of the middle eyebrow. These infiltrations should be very  
198 superficial with 1 IU up to 3 IU per infiltration.<sup>12</sup>

199 Treatment of the depressor supercillii muscle should be  
200 administered in patients with closely spaced and depressed  
201 eyebrows or with oblique J-shaped lines at the inner can-  
202 thus. It is performed using an infiltration point 1-1.5 cm  
203 above the canthal ligament, at a superficial level, with 1 IU  
204 up to 2 IU per injection.<sup>13</sup>

## 205 Orbicularis oculi muscle

### 206 Anatomy

207 The orbicularis oculi muscle controls eye opening. In addi-  
208 tion, along with the glabellar complex and the frontal  
209 muscle, it influences eyebrow position. The contraction of  
210 the lateral portion of the muscle is responsible for the  
211 appearance of horizontal wrinkles known as "crow's feet."  
212 The approach to the orbicularis oculi muscle differs  
213 between its lateral and medial portions.

### 214 Lateral portion treatment: "Crow's feet" and 215 eyebrow position

#### 216 Position

217 The classic approach involves 3 points: one located 1.5 cm  
218 lateral to the external canthal ligament; the other 2, one  
219 inferior and one superior to the former, are located more  
220 medially<sup>14</sup> (Fig. 3, left side of the face).

221 Five patterns of crow's feet wrinkles have been  
222 described.<sup>15</sup> The injection points are marked at the areas



223 **Figure 3** Left side with infiltration points for the orbicularis  
224 oculi muscle to treat external corner wrinkles. Classic points  
225 (red), lower edge point (blue), and points for lower eyelid wrin-  
226 kles (yellow). Right side with points for eyebrow elevation (pink  
227 points) and points for ocular opening (green points).  
228  
229  
230

231 of maximum contraction of the orbicularis muscle with the  
232 patient in a forced smile position. It is recommended to  
233 inject between 2 and 6 points, located 1 cm lateral to  
234 the orbital rim or 1.5 cm lateral to the canthal ligament,  
235 to prevent diffusion to muscles involved in ocular globe  
236 movement. In patients with a complete or extended contrac-  
237 tion pattern, a second line of more lateral points may be  
238 required.  
239  
240

### 241 Dose and infiltration depth

242 Injections should be superficial, with a total of 2 IU up to  
243 3 IU per point.  
244

### 245 Recommendations and precautions

- 246 1. Avoid excessively high doses to prevent a "frozen" smile  
247 appearance.  
248
- 249 2. In patients with eyelid bags or increased laxity of the  
250 subcutaneous tissue, injections below the external can-  
251 thal ligament should be avoided, and lower doses should  
252 be used.  
253
- 254 3. Treatment for lower palpebro-malar wrinkles should be  
255 performed with more medial and superficial injections of  
256 0.5 IU up to 1 IU to prevent diffusion to the zygomaticus  
257 major muscle, which may cause an asymmetrical smile.<sup>16</sup>  
258  
259  
260  
261  
262

245 4. Eyebrow tail elevation: To achieve greater elevation of  
246 the eyebrow tail, 2-3 infiltrations can be performed  
247 below the eyebrow, in its superolateral portion, with-  
248 out crossing the mediopupillary line. Infiltrations should  
249 be superficial, with a total of 1 IU up to 2 IU per point<sup>17,18</sup>  
250 (Fig. 3, upper right side of the face).

### 251 Medial portion treatment: eye opening

#### 252 Position

253 It should be injected at a point located 2 mm from the ciliary  
254 margin and at the mediopupillary zone. In some patients, a  
255 second point may be necessary just at the external corner  
256 of the eye (Fig. 3, right side of the face).

#### 257 Dose and infiltration depth

258 Infiltrations should be superficial, with doses of 1 IU up to  
259 2 IU to prevent toxin migration to the orbital septum.<sup>19</sup>

#### 260 Recommendations and precautions

261 1. Avoid in elderly patients, those with eyelid surgical pro-  
262 cedures, ectropion, dry eye, or morning eyelid edema.<sup>20</sup>

### 263 Nasal muscles

#### 264 Anatomy

265 Nasal muscles are the nasalis muscle and the levator labii  
266 superioris alaeque nasi (LLSAN). Their hyperactivity, along  
267 with that of the inner portion of the orbicularis oculi muscle,  
268 is responsible for the appearance of nasal scrunch wrinkles  
269 (Bunny lines), which are typically more prominent after  
270 blocking the glabellar complex.


#### 271 Position

272 The patient should be examined by asking them to forcibly  
273 show the upper dental arch or to make a displeased expres-  
274 sion (Fig. 4).

275 Treatment of nasal muscles is performed with 6 points  
276 that form a U on the nasal pyramid.<sup>21</sup> The nasalis muscle  
277 is blocked at the lateral nasal pyramid, always at the mid  
278 level of the line connecting the inner canthus of the eye and  
279 the nasal wing. The LLSAN is blocked at the lower portion  
280 of the nasal pyramid, at the beginning of the nasogenian  
281 groove. The inner portion of the orbicularis oculi muscle is  
282 blocked at a point next to the nasal root, close to the inner  
283 canthus.<sup>22</sup>

#### 284 Dose and infiltration depth

285 The injections should be superficial, with a total of 2 IU up  
286 to 3 IU for the nasalis muscle, 1 IU up to 2 IU for the inner  
287 portion of the orbicularis oculi muscle, and 1 IU up to 2 IU  
288 for blocking the LLSAN.



263 **Figure 4** Central nasal area with safety line and infiltration  
264 points for nasal wrinkles (red), on the left side, classic treat-  
265 ment points for gingival smile (yellow), alternative points for  
266 gingival smile at orbicularis oris muscle level (light blue). Bot-  
267 tom right of the image with points forming a triangle to treat  
268 the masseter (green) and safety line (dark blue).

#### 289 Recommendations and precautions

290 1. Gingival smile. This occurs due to excessive contraction  
291 of the LLSAN muscle. Treatment is administered with  
292 an injection point at the beginning of the nasogenian  
293 groove, located 1 cm superior and 2-3 mm lateral to the  
294 nasal opening. In more severe cases, a second point is  
295 required 1 cm lateral and 1 cm inferior to the former,  
296 at the intersection of the mediopupillary line and the  
297 nasogenian groove, coinciding with the convergence of  
298 the LLSAN and the zygomaticus minor muscle.<sup>23</sup> Gingival  
299 smile can also be treated by infiltrating the orbicularis  
300 oris muscle with 2 symmetrical injection points, located  
301 5 mm below the center of each nostril. This technique  
302 is easier and has less risk of diffusion,<sup>24</sup> although some  
303 authors consider it less effective.<sup>25</sup> The doses used are  
304 1 IU up to 2 IU per injection point, at a medium depth  
305 (Fig. 4, left side).  
306 2. An incorrect approach may elongate the lip and cause a  
307 false smile.<sup>26</sup>  
308 3. Nasal tip elevation. This can be achieved by blocking the  
309 depressor septi muscle with an infiltration of 2 IU up to  
310 3 IU at a medium depth at columella level.<sup>27</sup>

Q1

## 311 Masseter muscle

### 312 Anatomy

313 Treatment of the masseter muscle is indicated for patients  
314 with bruxism or those with a pronounced mandibular angle.

### 315 Position

316 A safety line is described that connects the mouth corner to  
317 the earlobe. Injections above this line can cause diffusion to  
318 muscles involved in chewing. The classic approach involves  
319 3 points in the shape of a triangle: 2 inferior points located  
320 1 cm from the mandibular border, and a third superior point  
321 forming the apex.<sup>28</sup> Alternatively, multipuncture techniques  
322 and those based on a single central injection point at the  
323 convergence of the masseter muscles have been described<sup>28</sup>  
324 (Fig. 4, right side of the face).

### 325 Dose and infiltration depth

326 In most patients, 24 IU is enough. Higher doses (up to 40 IU)  
327 may be used for greater pain reduction and longer-lasting  
328 effects.<sup>29</sup> Injections should be deep to avoid retrograde dif-  
329 fusion to more superficial muscles such as the risorius or  
330 platysma.

### 331 Recommendations and precautions

- 332 1. Flaccidity may worsen after masseter muscle treatment.
- 333 2. There is a compensatory increase in the volume of the  
334 temporalis muscle, reducing the hollowing of the tem-  
335 poral fossa.<sup>30</sup>

## 336 Orbicularis oris muscle

### 337 Anatomy


338 The contraction of the orbicularis oris muscle is responsible  
339 for the appearance of vertical wrinkles around the mouth,  
340 known as "barcode lines."

### 341 Position

342 Treatment is administered with 2-4 points located at the  
343 vermillion border or, at most, 1-2 mm above it. The injection  
344 points are marked at areas of maximum contraction of the  
345 orbicularis muscle with the lips contracted in a kissing posi-  
346 tion. They should be spaced laterally, at least, 5 mm from  
347 the philtrum, and 5 mm from the mouth corner (Fig. 5).

### 348 Dose and infiltration depth

349 Injections should be superficial, with 1 IU up to 2 IU per  
350 point.



351 **Figure 5** Infiltration point for the orbicularis oris (red) and  
352 mentalis muscles (green), infiltration points for the DAO, with  
353 the 3 upper-point technique or the classic technique with one  
354 upper point next to the commissure and the lower point on  
355 the mandibular border (blue), and infiltration points for the DLI  
(yellow points).

### 351 Recommendations and precautions

- 352 1. Within the first 2-3 weeks after injection, difficulty in  
353 blowing or mild incontinence when drinking may occur.
- 354 2. The lips may evert slightly, which can be beneficial for  
355 thin lips.<sup>31</sup>

## 356 Mentalis muscle

### 357 Anatomy

358 Mobilization of the mentalis muscle causes the appearance  
359 of orange peel skin on the chin and/or prominence of the  
360 labiomental fold.

### 361 Position

362 Injections are performed at a single point along the chin  
363 midline or else, at 2 different points 5 mm laterally from  
364 the midline<sup>32</sup> (Fig. 5).

365	<b>Dose and infiltration depth</b>	<b>Platysma muscle</b>	407
366	Injections should be deep, almost in contact to the bone,	<b>Anatomy</b>	408
367	with doses between 4 IU up to 10 IU for complete treatment	The platysma muscle has a bimodal movement. The upper	409
368	of the muscle. <sup>33</sup>	portion, along with the DAO, is responsible for the down-	410
		ward pull of the labial commissure and the appearance of	411
369	<b>Precautions</b>	the melolabial folds or “marionette lines”. <sup>37</sup> The lower por-	412
		tion of the platysma pulls the neck upward. Its hyperfunction	413
370	Subdermal touch-up injections of 1 IU up to 3 IU may be	causes platysmal bands, while the loss of tone causes hori-	414
371	needed centrally to avoid diffusion to the depressor of the	zontal neck wrinkles. <sup>38</sup>	415
372	lower lip (DLI). <sup>34</sup>	The approach to the platysma muscle has different objec-	416
		tives depending on whether its upper or lower portion is	417
		being treated.	418
373	<b>Depressor anguli oris muscle</b>		
374	<b>Anatomy</b>	<b>Treatment of the upper portion: melolabial</b>	419
		<b> folds or “marionette lines” and jaw contour</b>	420
375	The contraction of the depressor anguli oris (DAO) muscle is	<b>Position</b>	421
376	responsible, along with the platysma, for the downward pull	Treatment is administered using the Toxin lift and Nefertiti lift	422
377	of the labial commissure, contributing to the appearance of	techniques, which are based on 2 lines of points, superior	423
378	the melolabial folds or “marionette lines.”	and inferior, along the mandibular line. Injections are per-	424
		formed at 3–4 points in each line, distributed between the	425
379	<b>Position</b>	insertion of the DAO and the mandibular angle. <sup>39,40</sup> Alter-	426
		natively, it can be treated with 4 points forming a line 1 cm	427
380	Treatment of the DAO is administered with 2 points, one	above the mandibular border. The first point is located medi-	428
381	superior and one inferior, located on a line drawn among	ally, at the height of the oral commissure, with the other 3	429
382	the nasal wing, the oral commissure, and the mandibu-	points being located more laterally, closer to the mandibular	430
383	lar border. <sup>31</sup> The former point addresses the upper part of	angle <sup>41</sup> (Fig. 6).	431
384	the muscle and is located 1 cm lateral and inferior to the		
385	oral commissure, slightly lateral to the marionette line. The	<b>Dose and infiltration depth</b>	432
386	lower part of the DAO is treated from a second point 1 cm	Injections should be administered at 4–8 points with super-	433
387	superior to the mandibular border, lateral to the mental	ficial doses ranging from 2 IU up to 5 IU, with a total dose of	434
388	foramen and medial to the mandibular ligament (Fig. 5).	20 IU.	435
389	Alternatively, it can be treated only at its proximal part		
390	with 3 upper points forming a descending line underneath	<b>Treatment of the lower portion: platysmal</b>	436
391	the oral commissure. <sup>35</sup>	<b> bands and horizontal neck wrinkles</b>	437
		<b>Position</b>	438
392	<b>Dose and infiltration depth</b>	The treatment of prominent platysmal bands is performed	439
		using 2–6 points located on each band, spaced 1.5–2 cm	440
393	Doses of 2 IU up to 4 IU are recommended for treating the	apart. <sup>42</sup>	441
394	DAO. Injections should be superficial, with a total of 1 IU up	Treatment of horizontal neck wrinkles is administered	442
395	to 2 IU per injection.	using 5–10 points, spaced 1–1.5 cm apart, in 1 or 2 lines	443
		following the wrinkles. <sup>43</sup>	444
396	<b>Recommendations and precautions</b>	<b>Dose and infiltration depth</b>	445
		Injections should be superficial, with doses of 1 IU up to	446
397	1. To correctly identify the DAO, the muscle can be pal-	3 IU per point for platysmal bands and 1 IU up to 2 IU for	447
398	lated before treatment by asking the patient to show	horizontal wrinkles.	448
399	their lower dental arch.		
400	2. There is a risk of diffusion to the DLI, which could cause		
401	the contralateral lower lip to descend when smiling. <sup>36</sup>		
402	If this happens, it can be corrected by injecting 1 IU up		
403	to 2 IU into the DLI on the side where the commissure is		
404	descending.		
405	3. Treatment of DAO should be administered along with the		
406	upper portion of the platysma for optimal results.		

Q1



**Figure 6** Infiltration points for the mandibular border (red), platysmal bands (pink), and horizontal wrinkles (blue). Note: The image of the model has been generated by artificial intelligence.

### Recommendations and precautions

1. Errors in the approach to the lower portion of the platysma can cause swallowing issues and dysphonia due to diffusion to the infrahyoid muscles. Doses > 50 IU should be avoided, as well as injections in the central neck area where platysmal muscle fibers are less abundant.
2. Treatment of platysmal bands should be avoided in patients with excessive flaccidity.
3. The infiltration technique is easier with the patient seated or semi-reclined.

### Conclusions

Although botulinum toxin infiltration for esthetic purposes has been in practice for years, updates and changes based on the study of the anatomy and function of the muscles involved have been developed and should be known and applied. Being a generally safe treatment, the adverse effects due to excessive doses or unwanted diffusion to adjacent muscles must be understood.

Some patients may request treatment only for the upper third of the face or specific areas such as the LLSAN muscle for correcting a gingival smile. However, it is important to take a comprehensive approach to the face and neck to achieve more natural and harmonious results. Therapeu-

tic approach should be individualized, assessing the patient both at rest and in contraction to correctly locate the injection points and avoid treating certain muscles in case of contraindications.<sup>44</sup>

### Conflicts of interest

None declared.

### Acknowledgments

We wish to thank Dr. Alejandro Martín-Gorgojo.

### References

1. Cotofana S, Freytag DL, Frank K, Sattler S, Landau M, Pavicic T, et al. The bidirectional movement of the frontalis muscle: introducing the line of convergence and its potential clinical relevance. *Plast Reconstr Surg.* 2020;145:1155-62, <http://dx.doi.org/10.1097/PRS.0000000000006756>.
2. Swift A, Green JB, Hernandez CA, Aguilera SB, Fagien S, Gold MH, et al. Tips and tricks for facial toxin injections with illustrated anatomy. *Plast Reconstr Surg.* 2022;149:303e-12e, <http://dx.doi.org/10.1097/PRS.0000000000008708>.
3. El-Garem YF, Eid AA, Leheta TM. Locking the line of convergence by botulinum toxin type A for the treatment of dynamic forehead wrinkles. *J Cosmet Dermatol.* 2023;22:186-92, <http://dx.doi.org/10.1111/jocd.15468>.
4. Davidovic K, Melnikov DV, Frank K, Gavril D, Green JB, Freytag DL, et al. To click or not to click - the importance of understanding the layers of the forehead when injecting neuromodulators - a clinical, prospective, interventional, split-face study. *J Cosmet Dermatol.* 2021;20:1385-92, <http://dx.doi.org/10.1111/jocd.13875>.
5. Borba A, Matayoshi S, Rodrigues M. Avoiding complications on the upper face treatment with botulinum toxin: a practical guide. *Aesthetic Plast Surg.* 2022;46:385-94, <http://dx.doi.org/10.1007/s00266-021-02483-1>.
6. Jones IT, Fabi SG. The use of neurotoxins in the male face. *Dermatol Clin.* 2018;36:29-42, <http://dx.doi.org/10.1016/j.det.2017.09.005>.
7. Salti G, Ghersetich I. Advanced botulinum toxin techniques against wrinkles in the upper face. *Clin Dermatol.* 2008;26:182-91, <http://dx.doi.org/10.1016/j.clindermatol.2007.09.008>.
8. Cohen S, Artzi O, Heller L. Forehead lift using botulinum toxin. *Aesthet Surg J.* 2018;38:312-20, <http://dx.doi.org/10.1093/asj/sjx162>.
9. Solish N, Bertucci V, Green JB, Kane MAC. Optimizing outcomes when treating glabellar lines. *Aesthet Surg J.* 2023;43:786-8, <http://dx.doi.org/10.1093/asj/sjad087>.
10. de Almeida AR, da Costa Marques ER, Banegas R, Kadunc BV. Glabellar contraction patterns: a tool to optimize botulinum toxin treatment. *Dermatol Surg.* 2012;38:1506-15, <http://dx.doi.org/10.1111/j.1524-4725.2012.02505.x>.
11. de Sanctis Pecora C, Pinheiro MVB, Ventura Ferreira K, Jacobino de Barros Nunes G, Miot HA. The One21 technique: an individualized treatment for glabellar lines based on clinical and anatomical landmarks. *Clin Cosmet Investig Dermatol.* 2021;14:97-105, <http://dx.doi.org/10.2147/CCID.S281901>.
12. Cotofana S, Pedraza AP, Kaufman J, Avelar LET, Gavril DL, Hernandez CA, et al. Respecting upper facial anatomy for treating the glabella with neuromodulators to avoid medial brow ptosis-A refined 3-point injection technique. *J Cosmet Dermatol.* 2021;20:1625-33, <http://dx.doi.org/10.1111/jocd.14133>.



13. Domínguez-Duarte A. Aesthetic implications of depressor supercillii muscle block with botulinum toxin type A. *J Cosmet Dermatol.* 2022;21:1374-8, <http://dx.doi.org/10.1111/jocd.14856>.
14. Carruthers A, Carruthers J, De Boulle K, Lowe N, Lee E, Brin MF. Treatment of crow's feet lines and forehead lines with Botox (onabotulinumtoxin A): development, insights, and impact. *Medicine (Baltimore).* 2023;102, <http://dx.doi.org/10.1097/MD.00000000000032496>, e32496.
15. Cavallini M, Papagni M, Augelli F, Muti GF, Santorelli A, Raichi M. Heterogeneous crow's feet line patterns and customized botulinum toxin rejuvenating treatment. *J Cosmet Dermatol.* 2022;21:4294-300, <http://dx.doi.org/10.1111/jocd.15172>.
16. Li Y, Cai L, Zhang X, Yin B, Gong X, Li F, et al. Types of periocular wrinkles based on anatomical and contractile characteristics of participating periocular muscles: a modified classification method and personalized injection technique. *J Cosmet Dermatol.* 2022;21:5591-600, <http://dx.doi.org/10.1111/jocd.15197>.
17. Uygur S, Eryilmaz T, Bulam H, Yavuzer R, Latifoglu O. The quantitative effect of botulinum toxin A over brow height. *J Craniofac Surg.* 2013;24:1285-7, <http://dx.doi.org/10.1097/SCS.0b013e318292c80c>.
18. Ahn MS, Catten M, Maas CS. Temporal brow lift using botulinum toxin A. *Plast Reconstr Surg.* 2000;105:1129-35, <http://dx.doi.org/10.1097/00006534-200003000-00046>.
19. Flynn TC, Carruthers JA, Carruthers JA, Clark RE2nd. Botulinum A toxin (BOTOX) in the lower eyelid: dose-finding study. *Dermatol Surg.* 2003;29:943-50, <http://dx.doi.org/10.1046/j.1524-4725.2003.29257.x>.
20. Ascher B, Rzany BJ, Kestemont P, Redaelli A, Hendrickx B, Iozzo I, et al. International consensus recommendations on the aesthetic usage of ready-to-use abobotulinumtoxin A (alluzience). *Aesthet Surg J.* 2024;44:192-202, <http://dx.doi.org/10.1093/asj/sjad222>.
21. Tamura BM, Odo MY, Chang B, Cucé LC, Flynn TC. Treatment of nasal wrinkles with botulinum toxin. *Dermatol Surg.* 2005;31:271-5, <http://dx.doi.org/10.1111/j.1524-4725.2005.31072>.
22. Ramos HHA, Amaral V, de Oliveira Afonso LP, Campagnaro JCM, Gazzinelli HCG, Muzy G, et al. Advanced injection of botulinum toxin in the nasal muscles: a novel dynamic change in facial expression. *Aesthetic Plast Surg.* 2024;48:1511-21, <http://dx.doi.org/10.1007/s00266-023-03751-y>.
23. Rasteau S, Savoldelli C, Winter C, Lerhe B, Castillo L, Kestemont P. Botulinum toxin type A for the treatment of excessive gingival display - a systematic review. *J Stomatol Oral Maxillofac Surg.* 2022;123:e717-23, <http://dx.doi.org/10.1016/j.jormas.2022.05.016>.
24. Cengiz AF, Goymen M, Akcali C. Efficacy of botulinum toxin for treating a gummy smile. *Am J Orthod Dentofacial Orthop.* 2020;158:50-8, <http://dx.doi.org/10.1016/j.ajodo.2019.07.014>.
25. Kassir M, Babaei M, Hasanzadeh S, Rezaei Tavirani M, Razzaghi Z, Robati RM. Botulinum toxin applications in the lower face and neck: a comprehensive review. *J Cosmet Dermatol.* 2024;23:1205-16, <http://dx.doi.org/10.1111/jocd.16116>.
26. Trévidic P, Sykes J, Criollo-Lamilla G. Anatomy of the lower face and botulinum toxin injections. *Plast Reconstr Surg.* 2015;136:845-915, <http://dx.doi.org/10.1097/PRS.0000000000001787>.
27. Cohn JE, Greco TM. Advanced techniques for the use of neurotoxins in non-surgical facial rejuvenation. *Aesthetic Plast Surg.* 2020;44:1788-99, <http://dx.doi.org/10.1007/s00266-020-01691-5>.
28. Nikolis A, Enright KM, Masouri S, Bernstein S, Antoniou C. Prospective evaluation of incobotulinumtoxin A in the management of the masseter using two different injection techniques. *Clin Cosmet Investig Dermatol.* 2018;11:347-56, <http://dx.doi.org/10.2147/CCID.S164848>.
29. Chen Y, Tsai CH, Bae TH, Huang CY, Chen C, Kang YN, et al. Effectiveness of botulinum toxin injection on bruxism: a systematic review and meta-analysis of randomized controlled trials. *Aesthetic Plast Surg.* 2023;47:775-90, <http://dx.doi.org/10.1007/s00266-023-03256-8>.
30. Nikolis A, Enright KM, Rudolph C, Cotofana S. Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A. *J Cosmet Dermatol.* 2020;19:1294-300, <http://dx.doi.org/10.1111/jocd.13434>.
31. Wu DC, Fabi SG, Goldman MP. Neurotoxins: current concepts in cosmetic use on the face and neck-lower face. *Plast Reconstr Surg.* 2015;136:765-95, <http://dx.doi.org/10.1097/PRS.0000000000001750>.
32. Raspaldo H, Niforos FR, Gassia V, Dallara JM, Bellity P, Baspeyras M, et al. Lower-face and neck antiaging treatment and prevention using onabotulinumtoxin A: the 2010 multidisciplinary French consensus - Part 2. *J Cosmet Dermatol.* 2011;10:131-49, <http://dx.doi.org/10.1111/j.1473-2165.2011.00560.x>.
33. Guida S. Neurotoxin in the lower third of the face. *Dermatol Clin.* 2024;42:63-7, <http://dx.doi.org/10.1016/j.det.2023.06.002>.
34. Yi KH, Lee JH, Hu HW, Park HJ, Bae H, Lee K, et al. Novel anatomical guidelines for botulinum neurotoxin injection in the mentalis muscle: a review. *Anat Cell Biol.* 2023;56:293-8, <http://dx.doi.org/10.5115/acb.22.266>.
35. Moradi A, Shirazi A. A retrospective and anatomical study describing the injection of botulinum neurotoxins in the depressor anguli oris. *Plast Reconstr Surg.* 2022;149:850-7, <http://dx.doi.org/10.1097/PRS.0000000000008967>.
36. Auada Souto MP, Souto LRM. An unusual adverse event of botulinum toxin injection in the lower face. *J Cosmet Dermatol.* 2021;20:1381-4, <http://dx.doi.org/10.1111/jocd.13869>.
37. Sun W, Ma H, Song T. The underappreciated role of the platysma muscle in the perioral expressions in young adults. *Aesthet Surg J.* 2023;43:195-201, <http://dx.doi.org/10.1093/asj/sjac222>.
38. de Almeida ART, Romiti A, Carruthers JDA. The facial platysma and its underappreciated role in lower face dynamics and contour. *Dermatol Surg.* 2017;43:1042-9, <http://dx.doi.org/10.1097/DSS.0000000000001135>.
39. Jabbour SF, Kechichian EG, Awaida CJ, Tomb RR, Nasr MW. Botulinum toxin for neck rejuvenation: assessing efficacy and redefining patient selection. *Plast Reconstr Surg.* 2017;140:9e-17e, <http://dx.doi.org/10.1097/PRS.0000000000003429>.
40. Levy PM. The 'Nefertiti lift': a new technique for specific contouring of the jawline. *J Cosmet Laser Ther.* 2007;9:249-52, <http://dx.doi.org/10.1080/14764170701545657>.
41. Yi KH, Lee JH, Lee K, Hu HW, Lee HJ, Kim HJ. Anatomical proposal for botulinum neurotoxin injection targeting the platysma muscle for treating platysmal band and jawline lifting: a review. *Toxins (Basel).* 2022;14:868, <http://dx.doi.org/10.3390/toxins14120868>.
42. Germani M, Almeida CCMS, Munoz-Lora VRM, Rogério V, Moelhoff N, Freytag DL, et al. How to improve infraorbital hollows with neuromodulators - a clinical prospective interventional study about the application of facial biomechanics. *J Cosmet Dermatol.* 2023;22:2950-6, <http://dx.doi.org/10.1111/jocd.15970>.
43. Wu WTL. Microbotox of the lower face and neck: evolution of a personal technique and its clinical effects. *Plast Reconstr Surg.* 2015;136:925-1005, <http://dx.doi.org/10.1097/PRS.0000000000001827>.
44. Ruiz-Rodriguez R, Martin-Gorgojo A. Ten mistakes to avoid when injecting botulinum toxin [article in English, Spanish]. *Actas Dermosifiliogr.* 2015;106:458-64, <http://dx.doi.org/10.1016/j.ad.2015.04.003>.